BridgeBio Pharma Inc (BBIO) concluded trading on Thursday at a closing price of $36.81, with 7.25 million shares of worth about $266.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 46.23% during that period and on February 20, 2025 the price saw a gain of about 1.42%. Currently the company’s common shares owned by public are about 188.99M shares, out of which, 147.44M shares are available for trading.
Stock saw a price change of 15.20% in past 5 days and over the past one month there was a price change of 2.01%. Year-to-date (YTD), BBIO shares are showing a performance of 34.13% which decreased to -1.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.62 but also hit the highest price of $37.81 during that period. The average intraday trading volume for BridgeBio Pharma Inc shares is 2.57 million. The stock is currently trading 7.26% above its 20-day simple moving average (SMA20), while that difference is up 16.80% for SMA50 and it goes to 33.37% higher than SMA200.
BridgeBio Pharma Inc (NASDAQ: BBIO) currently have 188.99M outstanding shares and institutions hold larger chunk of about 76.17% of that.
The stock has a current market capitalization of $6.96B and its 3Y-monthly beta is at 1.07. It has posted earnings per share of -$2.85 in the same period. It has Quick Ratio of 3.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBIO, volatility over the week remained 7.33% while standing at 5.40% over the month.
Stock’s fiscal year EPS is expected to drop by -25.54% while it is estimated to increase by 30.30% in next year. EPS is likely to grow at an annualized rate of 65.51% for next 5-years, compared to annual growth of -3.04% made by the stock over the past 5-years.
On September 04, 2024, Piper Sandler Initiated their recommendations, while on March 21, 2024, Raymond James Resumed their ratings for the stock with a price target of $45. Stock get a Market perform rating from BMO Capital Markets on January 31, 2024.
